Organisation paid for research Program year 2025 Source: CMS Open Payments

Total Skin & Beauty Dermatology Cen

Neither a doctor nor a teaching hospital

Research payments

$835,428

88 payments

Through program year 2025, Total Skin & Beauty Dermatology Cen is reported as receiving $835,428 in research payments, across 88 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$116,931	49
2024	Research	$90,362	24
2023	Research	$107,347	5
2022	Research	$520,789	10

Breakdown

Who paid Research payments · program years 2022–2025

AbbVie, Inc. $835,428 88 payments

Studies the money was for Research payments · program years 2022–2025

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines $607,256 12 payments
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) $74,661 18 payments
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $44,651 13 payments
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) $17,943 10 payments
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) $15,066 3 payments
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis $12,194 13 payments
M21-416 BOTOX Ph3 Pivotal MMP $11,599 1 payment
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $10,793 3 payments
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) $7,973 2 payments
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study $7,804 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.